Tested Applications
| Positive WB detected in | A375 cells, human placenta tissue, HeLa cells |
| Positive IHC detected in | human skin cancer tissue, human brain tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | A549 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
21915-1-AP targets OAS3 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, hamster |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag16150 Product name: Recombinant human OAS3 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-350 aa of BC113746 Sequence: MDLYSTPAAALDRFVARRLQPRKEFVEKARRALGALAAALRERGGRLGAAAPRVLKTVKGGSSGRGTALKGGCDSELVIFLDCFKSYVDQRARRAEILSEMRASLESWWQNPVPGLRLTFPEQSVPGALQFRLTSVDLEDWMDVSLVPAFNVLGQAGSGVKPKPQVYSTLLNSGCQGGEHAACFTELRRNFVNIRPAKLKNLILLVKHWYHQVCLQGLWKETLPPVYALELLTIFAWEQGCKKDAFSLAEGLRTVLGLIQQHQHLCVFWTVNYGFEDPAVGQFLQRQLKRPRPVILDPADPTWDLGNGAAWHWDLLAQEAASCYDHPCFLRGMGDPVQSWKGPGLPRAGC Predict reactive species |
| Full Name | 2'-5'-oligoadenylate synthetase 3, 100kDa |
| Calculated Molecular Weight | 1087 aa, 121 kDa |
| Observed Molecular Weight | 100-120 kDa |
| GenBank Accession Number | BC113746 |
| Gene Symbol | OAS3 |
| Gene ID (NCBI) | 4940 |
| RRID | AB_2876880 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9Y6K5 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
The 2-prime,5-prime oligoadenylate synthetases (OASs), such as OAS3, are interferon-induced proteins characterized by their capacity to catalyze the synthesis of 2-prime,5-prime oligomers of adenosine (2-5As). It is also named as p100 OAS and belongs to the 2-5A synthase family. OAS3 is involved in inhibition of cellular protein synthesis and in viral infection resistance. This antibody may have weak cross-reaction with OAS1 protein due to the highly homology.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for OAS3 antibody 21915-1-AP | Download protocol |
| IHC protocol for OAS3 antibody 21915-1-AP | Download protocol |
| WB protocol for OAS3 antibody 21915-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The OAS3 Polyclonal antibody (Cat# 21915-1-AP) has 29 citations spanning journals including Science, Circulation, Immunity, Nature Cell Biology, Nature Communications, Molecular Cell, EMBO Journal, Cell Reports, FASEB Journal, and PLoS Pathogens. Research fields encompass antiviral immunity, OAS-RNase L pathway signaling, type I interferon responses, viral infections (EV71, Zika, RSV, poxvirus), cancer (pancreatic, ovarian, lung, glioblastoma), diabetes, psoriasis, liver injury, obesity, and proteomics.
| Species | Application | Title |
|---|---|---|
Circulation Nuclear eNOS Interacts With and S-Nitrosates ADAR1 to Modulate Type I Interferon Signaling and Endothelial Function. | ||
Immunity OAS cross-activates RNase L intercellularly through cell-to-cell transfer of 2-5A to spread innate immunity | ||
Nat Cell Biol Redox regulation of m6A methyltransferase METTL3 in β-cells controls the innate immune response in type 1 diabetes | ||
Nat Commun Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. | ||
